Abivax: Sofinnova Partners falls below 10% of voting rights
Similarly, Truffle Capital, acting on behalf of funds, declared that on October 24 it had crossed below the thresholds of 15% of voting rights and 10% of capital in Abivax, and held 7.86% of capital and 13.00% of voting rights in the biotech company.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction